Vancouver, British Columbia – TheNewswire – May 11, 2020 – Blackhawk Growth Corp. (CSE:BLR) (Frankfurt:0JJ) (OTC:BLRZF) (the “Corporation” or “Blackhawk“), is pleased to announce that after submitting its initial order on May 1, 2020 for 1,000 Innovita manufactured Covid-19 antibody testing kits, the Company can confirm that the kits arrived and were delivered to the healthcare clinic in Rocklin, California on May 6, 2020. These testing kits are being immediately distributed to healthcare professionals in the area.

“This is the start we were hoping for” said Frederick Pels, CEO of Blackhawk. “Showing that we can deliver these kits in such a short timeframe puts us vastly ahead of others in the space. The clinic is ecstatic, and we have begun negotiations on additional larger orders. A 5-day delivery time is phenomenal and I’m certain it will raise the attention of new buyers and assist us in our other ongoing negotiations. I look forward to keeping our shareholders updated as we continue to execute and do our part to flatten the curve.”

“We are extremely pleased to have been able to fulfill this order in such an efficient and timely fashion,” says James Saunders of Emergence Technology Pty. Ltd. “We pride ourselves in our ability to deliver for our partners and while everyone else in the market can’t get these kits for months, we were able to deliver them within a week. This accomplishment showcases our ability to leverage our relationship with the manufacturer to deliver antibody testing kits in the shortest lead time. The goal of this order was to prove that we are able to deliver these kits quicker than anyone else on the market and we look forward to delivering many more over the coming months.”

For further information please contact:

Frederick Pels, Chief Executive Officer


This email address is being protected from spambots. You need JavaScript enabled to view it.

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to the planned distribution of test kits and anticipated delivery times. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.